Delving into the Latest Updates on ANK-102 with Synapse

Overview

Basic Info

Drug Type

Cytokines

Synonyms

Target-

Mechanism-

Therapeutic Areas

Neoplasms

Active Indication

Neoplasms

Inactive Indication-

Originator Organization

Ankyra Therapeutics, Inc.Startup

Active Organization

Ankyra Therapeutics, Inc.Startup

Inactive Organization-

Drug Highest PhaseDiscovery

First Approval Date-

Regulation-

Modulatory effect on the murine self defense system by a newly discovered acidic polysaccharide (ANK-102) produced by P. tuberosa cells in liquid culture was examined. Pretreatment with ANK-102 deteriorated the murine survival against lethal infection of Listeria monocytogenes, an intracellular gram-positive bacterium eliminated mainly by macrophages through T-cell mediated immune response. Pretreatment with ANK-102 resulted in the accumulation of Mac 1 and Mac 2 positive cells in the peritoneal cavity of the infected animals and the reduction of Thy1.2 expression on the surface of the thymocytes. A new type of immunosuppressive polysaccharide ANK-102 was introduced.

100 Deals associated with ANK-102

Login to view more data